Wolfe Research upgraded Edwards Lifesciences (EW) to Peer Perform from Underperform without a price target following the Transcatheter Cardiovascular Therapeutics symposium. The firm now believes the company’s risks are unlikely to drive negative estimate revisions in the near term. It sees fair value for shares in the $70-$85 range. Wolfe no longer see negative revisions on Rdwards’ transcatheter aortic valve replacement growth or profitability in the short run.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $87 from $82 at Truist
- Edwards Lifesciences: Hold Rating Amidst Stable TAVR vs. SAVR Trial Outcomes
- Positive Outlook on Edwards Lifesciences Reinforced by PARTNER 3 Study Results
- Positive Long-Term Outlook for Edwards Lifesciences’ TAVR Procedures Reinforces Buy Rating
- Positive Outlook for Edwards Lifesciences Reinforced by Long-Term TAVR Data